Literature DB >> 20585074

By Jove! What is a clinician to make of JUPITER?

Sanjay Kaul1, Ryan P Morrissey, George A Diamond.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20585074     DOI： 10.1001/archinternmed.2010.189

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN： 0003-9926


× No keyword cloud information.
  20 in total

1.  Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes.

Authors:  Lori Mosca; Elizabeth Barrett-Connor; Nanette Kass Wenger
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

Review 2.  Targeting inflammation: impact on atherothrombosis.

Authors:  Maria Giulia Marini; Chiara Sonnino; Marco Previtero; Luigi M Biasucci
Journal:  J Cardiovasc Transl Res       Date:  2013-12-11       Impact factor: 4.132

3.  Epidemiology of cardioprotective pharmacological agent use in stable coronary heart disease.

Authors:  Krishna Kumar Sharma; Mukul Mathur; Rakesh Gupta; Soneil Guptha; Sanjeeb Roy; R S Khedar; Nishant Gupta; Rajeev Gupta
Journal:  Indian Heart J       Date:  2013-04-09

Review 4.  Novel treatments for cardiovascular disease prevention.

Authors:  Mark D Huffman; Deepak Bhatnagar
Journal:  Cardiovasc Ther       Date:  2011-05-31       Impact factor: 3.023

5.  The JUPITER trial: myth or reality?

Authors:  Ryan P Morrissey; George A Diamond; Sanjay Kaul
Journal:  Curr Atheroscler Rep       Date:  2011-10       Impact factor: 5.113

6.  Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3.

Authors:  Yu-Hung Chang; Der-Wei Hwu; Wei-Pin Kao; Yau-Jiunn Lee
Journal:  Rev Diabet Stud       Date:  2017-02-10

7.  Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk.

Authors:  Jon Conly; Fiona Clement; Marcello Tonelli; Brenda Hemmelgarn; Scott Klarenbach; Anita Lloyd; Finlay A McAlister; Don Husereau; Natasha Wiebe; Flora Au; Braden Manns
Journal:  CMAJ       Date:  2011-10-11       Impact factor: 8.262

8.  High-sensitivity C-reactive protein levels and health status outcomes after myocardial infarction.

Authors:  Yashashwi Pokharel; Puza P Sharma; Mohammed Qintar; Yuan Lu; Yuanyuan Tang; Philip Jones; Rachel P Dreyer; John A Spertus
Journal:  Atherosclerosis       Date:  2017-09-18       Impact factor: 5.162

9.  The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective.

Authors:  H N Hodis; P Collins; W J Mack; L Lind Schierbeck
Journal:  Climacteric       Date:  2012-06       Impact factor: 3.005

10.  C-reactive protein level and the incidence of eligibility for statin therapy: the multi-ethnic study of atherosclerosis.

Authors:  Devin M Mann; Daichi Shimbo; Mary Cushman; Susan Lakoski; Philip Greenland; Roger S Blumenthal; Erin D Michos; Donald M Lloyd-Jones; Paul Muntner
Journal:  Clin Cardiol       Date:  2012-08-09       Impact factor: 2.882
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.